Lifesci Capital Begins Coverage on Palvella Therapeutics (NASDAQ:PVLA)

Key Points

• Analysts at Lifesci Capital have initiated coverage on Palvella Therapeutics (NASDAQ:PVLA) with an "outperform" rating and a price target of $90.00, indicating a potential upside of 146.24%.
• The stock has received favorable ratings from multiple analysts, with an average consensus rating of "Buy" and a price target of $52.22.
• Palvella Therapeutics has recently faced significant funding interest, with hedge funds acquiring substantial stakes, contributing to institutional ownership of 40.11% of the company's stock.

Lifesci Capital started coverage on shares of Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) in a report issued on Monday, August 4th, Marketbeat reports. The brokerage set an "outperform" rating and a $90.00 price target on the stock. Lifesci Capital's target price indicates a potential upside of 115.78% from the stock's previous close. Lifesci Capital also issued estimates for Palvella Therapeutics' Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.81) EPS, FY2025 earnings at ($3.13) EPS and FY2026 earnings at ($3.64) EPS.

A number of other equities analysts have also commented on the stock. HC Wainwright reissued a "buy" rating and issued a $38.00 price target on shares of Palvella Therapeutics in a report on Wednesday, April 30th. Canaccord Genuity Group cut their price objective on shares of Palvella Therapeutics from $53.00 to $52.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Chardan Capital began coverage on shares of Palvella Therapeutics in a research note on Wednesday, April 9th. They issued a "buy" rating and a $50.00 price objective for the company. Finally, Truist Financial began coverage on shares of Palvella Therapeutics in a research report on Monday, July 21st. They set a "buy" rating and a $56.00 price target for the company. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $52.40.

Palvella Therapeutics Trading Up 2.0%

Shares of PVLA stock traded up $0.81 during trading on Monday, reaching $41.71. 78,021 shares of the company's stock traded hands, compared to its average volume of 93,671. The company has a market capitalization of $461.15 million, a P/E ratio of -3.45 and a beta of -0.01. The firm's 50-day moving average is $28.49 and its 200 day moving average is $24.39. Palvella Therapeutics has a 1 year low of $11.17 and a 1 year high of $41.72.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.74) earnings per share for the quarter, topping analysts' consensus estimates of ($3.40) by $2.66. As a group, sell-side analysts predict that Palvella Therapeutics will post -3.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Police & Firemen s Retirement System of New Jersey bought a new position in Palvella Therapeutics during the 2nd quarter worth about $37,000. Spire Wealth Management bought a new position in Palvella Therapeutics during the 1st quarter worth about $70,000. Citadel Advisors LLC bought a new position in Palvella Therapeutics during the 4th quarter worth about $125,000. Toronto Dominion Bank bought a new position in Palvella Therapeutics during the 4th quarter worth about $159,000. Finally, Geode Capital Management LLC bought a new position in Palvella Therapeutics during the 4th quarter worth about $171,000. 40.11% of the stock is currently owned by institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.